Everything You Need to Know About Familial hypocalciuric hypercalcemia for Step 1

Familial hypocalciuric hypercalcemia (FHH) is one of those “don’t fall for it” endocrine traps on Step 1: the labs look like primary hyperparathyroidism (high calcium, “inappropriately normal” or mildly high PTH), but the management is totally different. If you miss the key clue—low urine calcium—you can end up recommending an unnecessary parathyroidectomy that won’t fix anything.

Where this fits (big picture)

Hypercalcemia on USMLE usually makes you think:

• Primary hyperparathyroidism (most common outpatient cause)
• Malignancy (most common inpatient cause)
• Granulomatous disease, vitamin D intoxication, thiazides, etc.

FHH is the classic “benign inherited hypercalcemia with low urine calcium.” It’s high-yield because it mimics primary hyperparathyroidism but behaves differently.

---

Definition (what FHH is)

Familial hypocalciuric hypercalcemia is a benign, autosomal dominant condition caused by loss-of-function mutations in the calcium-sensing receptor (CaSR), leading to:

• Mild hypercalcemia (often lifelong)
• Low urinary calcium excretion (hypocalciuria)
• Normal or mildly elevated PTH

First Aid cross-reference

• Endocrine → Parathyroid disorders / Hypercalcemia
• Key memory hook in FA style: “FHH = low urine Ca; AD; CaSR mutation; no surgery.”

---

Pathophysiology (why the labs look the way they do)

The normal CaSR job (high yield)

The CaSR is expressed on:

• Parathyroid chief cells: senses serum calcium to regulate PTH secretion
• Renal tubules (esp. thick ascending limb and distal nephron): helps regulate urinary calcium excretion

When serum Ca$^{2+}$ is high, CaSR activation normally:

• Decreases PTH secretion
• Decreases renal calcium reabsorption → more calcium in urine

What goes wrong in FHH

In FHH, CaSR is less sensitive to calcium (loss-of-function), so the body “thinks” calcium is low even when it isn’t.

Resulting physiology:

• Parathyroid: needs higher Ca$^{2+}$ to suppress PTH → PTH is not suppressed (often normal-high)
• Kidney: “believes” Ca$^{2+}$ is low → increases calcium reabsorption → hypocalciuria

Step-style summary

• Serum Ca$^{2+}$: ↑ (mild)
• PTH: normal or ↑
• Urine Ca$^{2+}$: ↓
• Phosphate: often normal to low (PTH effect can lower phosphate, but PTH may be only mildly up)

---

Clinical presentation (how it shows up)

Most patients are asymptomatic and discovered incidentally.

Possible features (less common, but testable):

• Mild fatigue, constipation
• Rare: pancreatitis, chondrocalcinosis
• Family history of “high calcium” with no kidney stones

The big clinical contrast

• FHH: typically no kidney stones, minimal symptoms, benign course
• Primary hyperparathyroidism: kidney stones and bone issues are more typical (classic “stones, bones…”)

---

Diagnosis (the high-yield differentiator)

Key concept: urine calcium is LOW

The single most testable discriminator is low urinary calcium excretion.

Use the Calcium/Creatinine Clearance Ratio (CCCR)

This is a favorite on exams because it operationalizes “low urine calcium”:

$$\text{CCCR} = \frac{U_{Ca}\cdot S_{Cr}}{S_{Ca}\cdot U_{Cr}}$$

Typical cutoffs used for test questions:

• FHH: CCCR < 0.01
• Primary hyperparathyroidism: CCCR > 0.02
• 0.01–0.02: gray zone (diet, renal function, vitamin D status can confound)

💡

Practical Step tip: If the question gives you hypercalcemia + non-suppressed PTH, your next thought should be: check urine calcium/CCCR.

Helpful comparison table (FHH vs Primary Hyperparathyroidism)

Confirmatory testing

• Genetic testing for CaSR mutation can confirm (not always needed clinically, but fair game for “next best step” in vignettes with strong family history).

---

Treatment (what to do—and what NOT to do)

Mainstay

• Reassurance: benign condition, often no complications.
• Monitor if needed, but many patients require minimal follow-up.

What NOT to do

• Parathyroidectomy: classically not effective in FHH because the problem is CaSR signaling set-point, not a removable autonomous gland.

When medications come up

Occasionally, severe/symptomatic cases (rare) may be treated with a calcimimetic (e.g., cinacalcet) to activate CaSR and lower calcium—but for Step 1, the key is: usually no treatment.

---

High-yield associations & classic USMLE “tells”

1) “Mild hypercalcemia + normal/mildly high PTH + low urine calcium”

That triad screams FHH.

2) Strong family history

Autosomal dominant pattern:

• Parent and multiple relatives with “high calcium,” few symptoms

3) Trick scenario: post-parathyroidectomy hypercalcemia persists

If a stem mentions someone misdiagnosed with primary hyperparathyroidism who didn’t improve after surgery, think FHH.

4) Neonatal severe hyperparathyroidism (board-relevant extension)

If the question escalates to a newborn with severe hypercalcemia and very high PTH:

• Consider homozygous (or compound heterozygous) CaSR inactivation → neonatal severe hyperparathyroidism, a much more dangerous phenotype.

---

Rapid Step 1 memory anchors (what to write in the margin)

• FHH = CaSR loss-of-function → higher Ca set-point
• Hypercalcemia + hypocalciuria
• PTH normal/↑ (not suppressed)
• CCCR < 0.01
• Benign, AD, no surgery

---

Quick practice vignette (to lock it in)

A 22-year-old woman is found to have Ca$^{2+}$ of 11.2 mg/dL on routine labs. She feels well. PTH is 75 pg/mL (mildly elevated). Her mother “has always had high calcium.” 24-hour urine calcium is low.
Diagnosis: FHH
Next step: reassurance / no parathyroidectomy
Key testable metric: CCCR < 0.01